Literature DB >> 35590300

Surgical outcome of epicanthus and telecanthus correction by C-U medial canthoplasty with lateral canthoplasty in treatment of Blepharophimosis syndrome.

Ahmed Ali Amer1, Marwa Mahmoud Abdellah2, Nader Hussein Fouad Hassan3, Amr Mounir4.   

Abstract

PURPOSE: To evaluate the surgical outcome of epicanthus and telecanthus correction by C-U medial canthoplasty with lateral canthoplasty in Blepharophimosis Syndrome. PATIENTS AND METHODS: This was a retrospective single arm interventional study including 18 eyes of 9 patients with Blepharophimosis-ptosis-epicanthus inversus syndrome who presented to oculoplastic clinic, ophthalmology department, Qena university hospital in the period of between July 2020 to April 2021. All the patients had BPES with epicanthus and telecanthus. All cases were subjected to by C plasty with medial and lateral canthoplasty for correction of epicanthus and telecanthus correction followed by frontalis suspension surgery to correct the co-existing blepharoptosis.
RESULTS: The study included 9 cases of BPES, 6 boys and 3 girls, the mean age was 5.4 ± 1.5 in the study group, all patients had a positive family history for BPES. After surgery, the mean IICD decreased from 38.44 mm preoperatively to 32.8 mm postoperatively, with a mean difference of 6.2 mm (P <  0.001). Likewise, the mean PFL increased from 20.78 mm preoperatively to 26.63 mm postoperatively, with a mean difference of 5.8 mm (P <  0.001). Epicanthus skin fold disappeared in all cases and medical canthus could be seen with well healed difficulty seen scars.
CONCLUSION: C-U medial canthoplasty with lateral canthoplasty in Blepharophimosis Syndrome was found to be an effective procedure in the correction of epicanthus and telecanthus.
© 2022. The Author(s).

Entities:  

Keywords:  Blepharophimosis Syndrome; C-U medial canthoplasty; Epicanthus; Telecanthus; lateral canthoplasty

Mesh:

Year:  2022        PMID: 35590300      PMCID: PMC9118630          DOI: 10.1186/s12886-022-02455-2

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.086


  17 in total

1.  [Treatment of congenital eyelid syndrome (CES)].

Authors:  H Zhang; G Sun; Z Liu
Journal:  Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi       Date:  1997-05

2.  SURGICAL REPAIR OF THE SYNDROME OF EPICANTHUS INVERSUS, BLEPHAROPHIMOSIS AND PTOSIS.

Authors:  C C JOHNSON
Journal:  Arch Ophthalmol       Date:  1964-04

3.  One-stage correction for blepharophimosis syndrome.

Authors:  S-Y Wu; L Ma; Y-J Tsai; J Z-C Kuo
Journal:  Eye (Lond)       Date:  2006-11-17       Impact factor: 3.775

Review 4.  Correction of telecanthus in the blepharophimosis syndrome.

Authors:  T S Nowinski
Journal:  Int Ophthalmol Clin       Date:  1992

5.  Surgical strategy for congenital blepharophimosis syndrome.

Authors:  Wei-qing Huang; Qun Qiao; Ru Zhao; Xiao-jun Wang; Xue-quan Fang
Journal:  Chin Med J (Engl)       Date:  2007-08-20       Impact factor: 2.628

6.  Linkage of blepharophimosis syndrome in a large Indian pedigree to chromosome 7p.

Authors:  M Maw; B Kar; J Biswas; P Biswas; D Nancarrow; R Bridges; G Kumaramanickavel; M Denton; S S Badrinath
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

7.  One-stage repair of blepharophimosis: a new method.

Authors:  N Karacaoğlan; U Sahin; U Ercan; N Bozdogan
Journal:  Plast Reconstr Surg       Date:  1994-06       Impact factor: 4.730

8.  Blepharophimosis, ptosis, epicanthus inversus syndrome (BPES syndrome)

Authors:  C Oley; M Baraitser
Journal:  J Med Genet       Date:  1988-01       Impact factor: 6.318

9.  Multistage correction of blepharophimosis: our rationale for 18 cases.

Authors:  Huiyan Li; Dongmei Li; Ying Jie; Yin Qin
Journal:  Aesthetic Plast Surg       Date:  2009-02-10       Impact factor: 2.326

10.  Relationship between lower eyelid epiblepharon and epicanthus in Korean children.

Authors:  Dong Hoon Shin; Kyung In Woo; Yoon-Duck Kim
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.